S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Authors:
- Lawrence P. LeichmanLLLawrence P. Leichman
- Bryan H. GoldmanBGBryan H. Goldman
- Pierre O. BohanesPBPierre O. Bohanes
- Heinz J. LenzHLHeinz J. Lenz
- Charles R. ThomasCTCharles R. Thomas
- Kevin G. BillingsleyKBKevin G. Billingsley
- Christopher L. CorlessCCChristopher L. Corless
- Syma IqbalSISyma Iqbal
- Philip J. GoldPGPhilip J. Gold
- Jacqueline K. BenedettiJBJacqueline K. Benedetti
- Kathleen D. DanenbergKDKathleen D. Danenberg
- Charles D. BlankeCBCharles D. Blanke
- 1 December 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (34) , 4555-4560
Abstract
Purpose: Pathologic complete response (pCR) after neoadjuvant therapy for locally advanced esophageal adenocarcinoma is associated with improved survival. The Southwest Oncology Group designed a trimodality, phase II, single-arm trial with objectives of achieving a pCR rate of 40% with prospective exploratory analyses of intratumoral molecular markers postulated to affect response and survival.Patients and Methods: Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m2on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m2/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1.8 Gy/d for 25 fractions; surgery was performed 28 to 42 days after neoadjuvant therapy. Chemotherapy was planned after surgery. Tumors were analyzed for mRNA expression and polymorphisms in genes involved in drug metabolism and DNA repair.Results: Ninety-three patients were evaluable. Two deaths (2.2%) were attributable to preoperative therapy, and two deaths (2.2%) were attributable to surgery. Grade 3 and 4 toxicities were recorded for 47.3% and 19.4% of patients, respectively. Seventy-nine patients (84.9%) underwent surgery; 67.7% of patients had R0 resections. Twenty-six patients (28.0%) had confirmed pCR (95% CI, 19.1% to 38.2%). At a median follow-up of 39.2 months, estimates of median and 3-year overall survival (OS) were 28.3 months and 45.1%, respectively. Intratumoral ERCC-1 gene expression was inversely related to progression-free survival and OS.Conclusion: Neoadjuvant oxaliplatin, PI-FU, and EBRT for esophageal adenocarcinoma is active and tolerable. Because the regimen failed to meet the primary end point, it does not define a new standard. However, future trials can be built on this platform to validate the role of ERCC-1 in determining the best systemic regimen for individual patients.Keywords
This publication has 19 references indexed in Scilit:
- Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response and those with partial or no response?The Journal of Thoracic and Cardiovascular Surgery, 2009
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781Journal of Clinical Oncology, 2008
- Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Expression of Genes Related to Activity of Oxaliplatin and 5-Fluorouracil in Endoscopic Biopsies of Primary Esophageal Cancer in Patients Receiving Oxaliplatin, 5-Flourouracil and Radiation: Characterization and Exploratory Analysis with SurvivalJournal of Chemotherapy, 2006
- Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trialThe Lancet Oncology, 2005
- High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal CancerClinical Cancer Research, 2005
- Oxaliplatin in Combination With Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal CancerJournal of Clinical Oncology, 2002
- A Comparison of Multimodal Therapy and Surgery for Esophageal AdenocarcinomaNew England Journal of Medicine, 1996
- PRACTICALp-VALUE ADJUSTMENT FOR OPTIMALLY SELECTED CUTPOINTSStatistics in Medicine, 1996